Lantern Pharma Inc. (NASDAQ:LTRN – Get Free Report) shares rose 2.3% during mid-day trading on Tuesday . The company traded as high as $4.09 and last traded at $4.04. Approximately 30,390 shares traded hands during mid-day trading, a decline of 80% from the average daily volume of 151,501 shares. The stock had previously closed at $3.95.
Lantern Pharma Trading Down 2.0 %
The firm has a market cap of $41.36 million, a price-to-earnings ratio of -2.40 and a beta of 1.56. The firm’s 50-day moving average is $4.08 and its 200-day moving average is $5.46.
Lantern Pharma (NASDAQ:LTRN – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.09. During the same quarter last year, the firm earned ($0.44) EPS. Analysts forecast that Lantern Pharma Inc. will post -2.12 EPS for the current fiscal year.
Institutional Trading of Lantern Pharma
About Lantern Pharma
Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.
See Also
- Five stocks we like better than Lantern Pharma
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- ETF Screener: Uses and Step-by-Step Guide
- KB Home Slips After Earnings: What’s Next for Homebuilders?
- What does consumer price index measure?
- Micron Stock Soars as AI Demand Fuels Big Q4 Earnings Beat
Receive News & Ratings for Lantern Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantern Pharma and related companies with MarketBeat.com's FREE daily email newsletter.